Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00150462
Other study ID # PX-171-002
Secondary ID
Status Completed
Phase Phase 1
First received September 6, 2005
Last updated April 28, 2017
Start date September 2005
Est. completion date October 2009

Study information

Verified date April 2017
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date October 2009
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Written informed consent in accordance with federal, local, and institutional guidelines

2. Males and females =18 years of age

3. Histologically confirmed diagnosis of one of the hematologic malignancies below:

- Multiple myeloma (MM)

- Non-Hodgkin's lymphoma (NHL)

- Waldenström's Macroglobulinemia (WM)

- Hodgkin's disease (HD)

4. Subjects who are refractory or relapsed following at least two prior therapies

5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

6. Adequate cardiovascular function without symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction in the previous six months

7. Adequate hepatic function, with bilirubin < 2.0 times the upper limit of normal, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of < 3.0 times the upper limit of normal

8. Total white blood cell (WBC) count = 2,000/mm³, absolute neutrophil count (ANC) = 1000/mm³, hemoglobin = 8.0 g/dL, and platelet count = 50,000/mm³

- Screening ANC should be independent of granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for = 1 week and of pegylated G-CSF for = 2 weeks)

- Subjects receiving supportive care including erythropoietin, darbepoetin and/or bisphosphonates can continue to do so, but must be transfusion independent; subjects receiving erythropoietic support must remain on the same dose for the first 28 days of study participation

9. An estimated creatinine clearance of = 30 mL/min, calculated using the formula of Cockroft and Gault

10. Serum creatinine = 2.0 mg/dL

11. Uric acid, if elevated, must be corrected to within laboratory normal range prior to dosing

12. Female subjects of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test. Male subjects must use an effective barrier method of contraception throughout the study and for three months following the last dose if sexually active with a female of child-bearing potential.

Exclusion Criteria:

1. Female subjects who are pregnant or lactating

2. Subjects who are transfusion dependent

3. Subjects with NHL or HL who have received steroid therapy in the previous seven days

4. Subjects with MM or Waldenström's Macroglobulinemia who have received steroid therapy in the previous three weeks, except for MM subjects in the Carfilzomib + DEX Expansion Cohort, where previous treatment with dexamethasone will be allowed. The dose and schedule of administration of dexamethasone will be adjusted to that used in the protocol

5. Radiation, chemotherapy, or immunotherapy in the previous four weeks, or subjects who, in the judgment of the Investigator, have not recovered from the effects of previous therapy

6. For the Dose Escalation period, subjects who have received prior radioimmunotherapy with anti-cluster of differentiation (CD)20 monoclonal antibodies such as Bexxar® or Zevalin®; subjects treated with these products will be allowed in the Dose Expansion period

7. Subjects who have received allogeneic stem cell transplant therapy

8. Subjects with NHL or HL who have received autologous stem cell transplant therapy and have relapsed within 100 days of therapy

9. Rituxan therapy within three months before Day 1 unless there is evidence of disease progression

10. Major surgery within three weeks before Day 1

11. Congestive heart failure (CHF) (New York Heart Association class III to IV)

12. Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose

13. Subjects who are known or suspected of having human immunodeficiency virus (HIV) infection or who are HIV seropositive

14. Active hepatitis A, B, or C infection; or positive for Hepatitis C ribonucleic acid (RNA) or hepatitis B antigen

15. Non-hematologic malignancy within the past three years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer with stable prostate specific antigen (PSA) levels for three years

16. Subjects with treatment-related myelodysplastic disorder

17. Subjects with known brain metastasis (active central nervous system [CNS] disease only)

18. Serious psychiatric or medical conditions that could interfere with treatment

19. Participation in an investigational therapeutic study within one month prior to Day 1

20. Significant neurotoxicity (Grade 2 or higher with pain) at the time of study initiation

21. Concurrent therapy with approved or investigative anticancer therapeutics

22. Subjects with previous hypersensitivity to bortezomib injection

23. Subjects with contraindications to receiving allopurinol

24. Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment

25. Subjects with known or suspected amyloidosis

26. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis

Study Design


Intervention

Drug:
Carfilzomib
Administered as an IV bolus dose
Dexamethasone
Administered orally prior to carfilzomib

Locations

Country Name City State
United States Tower Cancer Research Foundation Beverly Hills California
United States Herbert Irving Comprehensive Cancer Center, Columbia University New York New York
United States Memorial Sloan Kettering Cancer Center New York New York
United States Weil Medical College of Cornell University New York New York
United States H. Lee Moffitt Cancer Center and Research Institute Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Dose-limiting Toxicities (DLTs) A DLT was defined as any of the following occurring in the first 28 days of study participation:
Nonhematologic:
> Grade 2 neuropathy with pain
= Grade 3 nonhematologic toxicity (excluding nausea, vomiting, or diarrhea)
= Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic/antidiarrheal therapy
Hematologic:
Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 × 10ˆ9/L) lasting = 14 days without hematopoietic growth factor support
Febrile neutropenia (ANC < 1.0 × 10ˆ9/L with a fever = 38.3°C)
Grade 4 thrombocytopenia (platelets < 25.0 × 10ˆ9/L) or thrombocytopenia associated with bleeding.
Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0.
28 days
Primary Maximum Observed Plasma Concentration of Carfilzomib (Cmax) Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Primary Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax) Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Primary Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Primary Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib Cycle 1, Day 1 at predose, 5, 15, and 30 minutes, and 1, 2, 4, and 24 hours post dose.
Secondary Best Clinical Response to Treatment Disease response criteria for NHL were according to the International Working Group Criteria for Non-Hodgkin's Lymphoma. Disease response criteria for Multiple Myeloma were according to the European Group for Blood and Marrow Transplantation (EBMT). Disease response criteria for WM were according to the consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. The disease response criteria for Hodgkin's Lymphoma are defined as follows:
Complete response: total resolution of measurable disease parameters.
Partial response: a = 50% resolution without the appearance of new disease.
Stable disease: between < 50% resolution and = 25% increases in measurable disease parameters without appearance of new disease.
Progressive disease: an increase of > 25% in measurable disease parameters.
Best clinical response is the best response observed from the start of study treatment until disease progression or death.
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Secondary Duration of Response Duration of objective response is defined as the time from the date of first documented assessment of clinical response (confirmed or unconfirmed complete response, partial response, or minimal response) to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment.
Median duration of response was calculated using the Kaplan-Meier method.
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Secondary Time to Progression Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment.
Median time to progression was calculated using the Kaplan-Meier method.
From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
Secondary Progression-free Survival Progression-free survival is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease or death, whichever comes first, plus one day. Participants without tumor progression or death were censored at the date of their last valid clinical response assessment. Median progression-free survival was calculated using the Kaplan-Meier method. From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1